Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-119 in drug-naïve type 2 diabetes mellitus
NCT04504370Phase 3Completed
- Sponsor
- PegBio
- Start
- Apr 2020
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of visepegenatide in type 2 diabetes mellitus (T2DM), sponsored by PegBio. Started Apr 2020; status: completed.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04504370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504370.